Seeking Alpha
 

InterMune, Inc. (ITMN)

- NASDAQ
ITMN is defunct.
Show Summaries  |  Hide Summaries
  • Aug. 25, 2014, 12:46 PM
    | Comment!
  • Aug. 25, 2014, 11:21 AM
    • Roche's (OTCQX:RHHBY +0.6%) $8.3B acquisition of InterMune (ITMN +35.7%) fuels an inflow of money into the biotech sector today. The iShares NASDAQ Biotech Index ETF (IBB +2.2%) is up on average volume.
    • ETFs: BIB, BIS
    | 1 Comment
  • Aug. 25, 2014, 9:11 AM
    | 1 Comment
  • Aug. 25, 2014, 7:12 AM
    • Shares of Chugai Pharmaceutical Co. dropped over 9% on the Tokyo exchange after Roche (OTCQX:RHHBY) decided to spend its money on InterMune (NASDAQ:ITMN) instead. According to Chugai, "it is in no way in the process of reviewing any plan to become a wholly owned subsidiary of Roche."
    | Comment!
  • Aug. 24, 2014, 5:31 PM
    • Roche (OTCQX:RHHBY, OTCPK:RHHBF) will pay $74/share for InterMune (NASDAQ:ITMN), a 38% premium to its Friday close and 63% higher than Aug. 12 when news of a potential sale emerged.
    • The deal gives Roche access to pirfenidone, which targets idiopathic pulmonary fibrosis, a disease that causes tissue deep in the lungs to become thick and scarred over time. Analysts predict pirfenidone will generate $1B in global sales by 2019.
    • Pirfenidone joins Roche’s stable of pulmonary treatments, including Pulmozyme for cystic fibrosis, Xolair for asthma, and in-development asthma drug lebrikizumab. Roche plans to speed pirfenidone’s U.S. start-up and help get insurance coverage for the medicine.
    • Press release
    | 7 Comments
  • Aug. 13, 2014, 1:25 PM
    • Shares of InterMune (ITMN +14.3%) spike on a 2x surge in volume in response to rumors that Roche (OTCQX:RHHBY +0.4%), Sanofi (SNY +0.7%), Glaxo (GSK -0.1%) and Actelion (OTCPK:ALIOF) (OTC:ACIOY) are preparing offers. Trading in ITMN shares was halted briefly at 1:00 pm EDT due to abnormal volatility.
    | 1 Comment
  • Aug. 6, 2014, 4:25 PM
    • InterMune (ITMN -1.1%) Q2 results: Esbriet Sales: $35.7M (147.9%); Operating Loss: ($62.4M) (-19.3%); Net Loss: ($71.2M) (-13.2%); Loss Per Share: ($0.72) (+6.5%); Quick Assets: $560.2M (+44.8%).
    • No guidance given.
    | Comment!
  • Aug. 6, 2014, 4:05 PM
    • InterMune (NASDAQ:ITMN): Q2 EPS of -$0.72 misses by $0.15.
    • Revenue of $35.7M (+147.9% Y/Y) beats by $1.74M.
    • Press Release
    | Comment!
  • Jul. 17, 2014, 3:49 PM
    • The FDA grants Breakthrough Therapy Designation (BTD) to InterMune's (ITMN -2.4%) pirfenidone for the treatment of idiopathic pulmonary fibrosis. Under this designation the agency expedites the development and review of the drug. The company resubmitted its NDA in May with a target review period of six months.
    | Comment!
  • Jul. 3, 2014, 7:13 AM
    • The FDA acknowledges the receipt of Intermune's (ITMN) resubmitted NDA for pirfenidone. The PDUFA date in November 23, 2014. The agency sent the company a CRL in May 2010 recommending an additional Phase 3 clinical trial to support the efficacy of the product. Pirfenidone is being developed as a treatment for idiopathic pulmonary fibrosis in adult patients.
    | Comment!
  • Jul. 2, 2014, 10:24 AM
    • Demonstrating the value of convertible debt, certain holders of InterMune's (ITMN -0.6%) Convertible Senior Notes exchange the debt for shares in several private transactions.
    • On June 30 and July 1 certain holders of the company's 2.50% Convertible Senior Notes due 2017 (the "2017 Notes") exchange $41M in aggregate principal amount of the debt for 3,185,703 shares of ITMN common stock ($12.87/share) plus $1,332,500 plus accrued unpaid interest. Based on today's price of ~$44 per share, this represents a tidy $100.5M gain on principal (($44 x 3,185,703 + 1.3M) - 41M).
    • Also on July 1, certain other holders of the 2017 Notes exchanged $11.93M in aggregate principal amount for 908,423 shares of common stock plus $1,213,648 representing a conversion price of $12.87 per share and a gain on principal of $29.3M.
    • Also on July 1, certain holders of the company''s 5.00% Convertible Senior Notes due 2015 exchange $16.86M in aggregate principal amount of the notes for 893,008 shares of common stock plus $674,400 representing a conversion price of $18.88 and a gain on principal of $23.1M.
    • InterMune expects to issue all shares by July 7.
    • 8-K
    | Comment!
  • May 27, 2014, 8:24 AM
    • It had to complete another Phase 3 trial, but Intermune (ITMN) finally resubmits its NDA for pirfenidone. The FDA sent the company a CRL in May 2010 requiring an additional study to support the drug's efficacy in idiopathic pulmonary fibrosis (IPF).
    • CEO Dan Welch says his organization will be able to launch the product in Q1 2015 if the FDA approves it within six months.
    • Pirfenidone is currently approved for sale in the EU, Norway, Iceland, Canada, Japan, China, India, South Korea, Argentina and Mexico.
    | Comment!
  • May 20, 2014, 5:38 PM
    • Top gainers, as of 5:15 p.m.: STAR +11.8%. HERO +7.3%. DFS +4.4%. UVXY +1.7%. ITMN +1.6%.
    • Top losers, as of 5:15 p.m.: IVZ -5.1%. PVCT -3.7%. INTU -3.5%. RMBS -2.8%. [[DNOWw]] -2.6%.
    | 1 Comment
  • May 19, 2014, 12:48 PM
    | Comment!
  • May 19, 2014, 12:45 PM
    | Comment!
  • May 19, 2014, 9:13 AM
    | 1 Comment
Visit Seeking Alpha's
Company Description
InterMune, Inc., is a biotechnology company. It is engaged in the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States